Technical Analysis for ONCR - Oncorus, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | N/A | Down |
| Historical ONCR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Inside Day | Range Contraction | 0.00% | |
| Calm After Storm | Range Contraction | 1.44% | |
| New 52 Week Closing Low | Bearish | 3.33% | |
| Hot IPO Pullback | Bullish Swing Setup | 3.33% | |
| Calm After Storm | Range Contraction | 3.33% | |
| Hot IPO Pullback | Bullish Swing Setup | -0.26% | |
| Hot IPO Pullback | Bullish Swing Setup | -2.94% | |
| NR7 | Range Contraction | -2.94% | |
| Inside Day | Range Contraction | -2.94% | |
| Hot IPO Pullback | Bullish Swing Setup | -2.15% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakout | 3 days ago | |
| Down 1% | 3 days ago | |
| Up 3% | 3 days ago | |
| Up 2% | 3 days ago | |
| Up 1% | 3 days ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
- Sector: Healthcare
- Industry: Biotechnology
Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Oncolytics Biotech Brain Cancer Oncolytic Virus
Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Oncolytics Biotech Brain Cancer Oncolytic Virus
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 19.3 |
| 52 Week Low | 14.6 |
| Average Volume | 112,275 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 0.00 |
| 10-Day Moving Average | 15.95 |
| Average True Range | 1.45 |
| ADX | 0.0 |
| +DI | 26.15 |
| -DI | 13.00 |
| Chandelier Exit (Long, 3 ATRs ) | 14.96 |
| Chandelier Exit (Short, 3 ATRs ) | 18.94 |
| Upper Bollinger Band | 0.00 |
| Lower Bollinger Band | 0.00 |
| Percent B (%b) | 0.0 |
| BandWidth | 0.00 |
| MACD Line | -0.16 |
| MACD Signal Line | -0.07 |
| MACD Histogram | -0.084 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 16.70 | ||||
| Resistance 3 (R3) | 16.70 | 16.30 | 16.50 | ||
| Resistance 2 (R2) | 16.30 | 15.99 | 16.30 | 16.43 | |
| Resistance 1 (R1) | 15.90 | 15.81 | 16.10 | 15.90 | 16.37 |
| Pivot Point | 15.50 | 15.50 | 15.60 | 15.50 | 15.50 |
| Support 1 (S1) | 15.10 | 15.19 | 15.30 | 15.10 | 14.63 |
| Support 2 (S2) | 14.70 | 15.01 | 14.70 | 14.57 | |
| Support 3 (S3) | 14.30 | 14.70 | 14.50 | ||
| Support 4 (S4) | 14.30 |
